BEAM
Beam Therapeutics Inc (BEAM)
Healthcare • NASDAQ • $32.32+2.70%
- Symbol
- BEAM
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $32.32
- Daily Change
- +2.70%
- Market Cap
- $3.33B
- Trailing P/E
- N/A
- Forward P/E
- -6.81
- 52W High
- $36.44
- 52W Low
- $15.35
- Analyst Target
- $51.13
- Dividend Yield
- N/A
- Beta
- 2.26
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, i…
Company websiteResearch BEAM on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.